Charlotte, North Carolina (February 18, 2005) - BurnsAdler Pharmaceuticals, Inc. announced today that they have partnered with Sigma-Tau S.p.A. for the promotion and distribution of Natulan® (procarbazine) in Latin America and the Caribbean. Natulan® is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) treatment regimen. Natulan® was marketed globally by Roche before being acquired by Sigma-Tau.

Banks Bourne, President of BurnsAdler remarked, "Natulan® is well known by hematologists and oncologists throughout the world. We look forward to bringing back this life saving medication to patients throughout Latin America and the Caribbean."

Procarbazine was discovered in the late 1950's during a search for monoamine oxidase (MAO) inhibitors with less serious side effects. As early as 1962, clinical trials were reported describing procarbazine's effectiveness in Hodgkin's disease. Procarbazine is a unique antineoplastic agent with multiple sites of action. It inhibits incorporation of small DNA precursors, as well as RNA and protein synthesis. Procarbazine is not cross-resistant with other alkylating agents.

Sigma-Tau is a leading research-based Italian pharmaceutical company with annual revenues of approximately € 620 million and over 2400 employees worldwide. Therapeutic areas in which the company's research and development are focused include: oncology, neurology, cardiovascular, gastroenterology, metabolism and immunology. Sigma-Tau has operating subsidiaries throughout Europe and the U.S. and maintains a presence in all of the world's major pharmaceutical markets.

BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler's portfolio currently includes products in the following fields: cardiovascular, orthopaedic, oncology and epilepsy.

For additional information about this news release contact Bryan Somerville at +1.704.552.8410 Ext. 223. For additional information about BurnsAdler, please refer to the company's website at www.burnsadler.com.